Format

Send to

Choose Destination
  • Filters activated: Field: Title Word. Clear all
Curr Opin Pharmacol. 2012 Aug;12(4):486-90. doi: 10.1016/j.coph.2012.02.009. Epub 2012 Mar 5.

IL-36 in psoriasis.

Author information

1
Inflammation Research, Amgen Inc., Seattle, WA 98119, United States.

Abstract

Psoriasis is a common but severe skin disease with significant health consequences, both physical and psychological. Evidence has emerged during the past several years pointing to a key role for IL-36 in psoriasis. Overexpression of IL-36 in mouse skin leads to a disease quite similar to human plaque psoriasis, and inhibition of IL-36 in human psoriatic skin ameliorates the inflammation. Loss of the natural antagonist of IL-36, IL-36Ra, results in a different, more severe skin disease known as pustular psoriasis. These effects are likely a consequence of the actions of IL-36 both on cells of the immune system as well as on components of skin including fibroblasts and keratinocytes.

PMID:
22398321
DOI:
10.1016/j.coph.2012.02.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center